He is being serious. If you listen to any of the conference calls, you will hear this discussed. They also have extremely high margins on the product, so if it gets approved and it is accepted by the medical community, then there is a good possibility the price will jump (as it will be valued in the future based on revenue and EBITDA margins. A very reasonable multiple prices this company at levels significantly higher than it is currently at).
Most recent bio tech deals have been going for 10 times revenues!! US mkt is 240,000 cases per year. CEO estimates $750 million in US market so thats $3,000 per use. Per use is irrelevant. 750 million dollar mkt valued at ten times is a lot higher than current price. meaning this is still potential 10 bagger. I do caution that all we have is a press release. FDA likes the data so I would be cautious.